Scandion Oncology A/S (SCOL) - Cash Flow Conversion Efficiency

Latest as of December 2024: -0.220x

Based on the latest financial reports, Scandion Oncology A/S (SCOL) has a cash flow conversion efficiency ratio of -0.220x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.82 Million ≈ $-195.65K USD) by net assets (Skr8.27 Million ≈ $889.77K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SCOL company net worth for the company's overall valuation and market capitalisation.

Scandion Oncology A/S - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Scandion Oncology A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Scandion Oncology A/S Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scandion Oncology A/S ranked by their cash flow conversion efficiency. See SCOL operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Kiliaro AB ST:KILI	2.808x
ECORUB AB B F:7M8	-3.107x
IMC Exploration Group Public Limited Company LSE:IMC	-0.458x
Ceps PLC LSE:CEPS	0.229x
Advanced Info Service Public Company Limited F:AISF	0.311x
Headlam Group LSE:HEAD	-0.182x
BOOSH PLANT-BASED BRANDS F:77I	N/A
Petros Pharmaceuticals Inc NASDAQ:PTPI	0.156x

Annual Cash Flow Conversion Efficiency for Scandion Oncology A/S (2017–2024)

The table below shows the annual cash flow conversion efficiency of Scandion Oncology A/S from 2017 to 2024. View SCOL stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr8.27 Million ≈ $889.77K	Skr-27.52 Million ≈ $-2.96 Million	-3.328x	-104.45%
2023-12-31	Skr31.12 Million ≈ $3.35 Million	Skr-50.67 Million ≈ $-5.45 Million	-1.628x	-64.88%
2022-12-31	Skr70.33 Million ≈ $7.57 Million	Skr-69.44 Million ≈ $-7.47 Million	-0.987x	-107.29%
2021-12-31	Skr104.54 Million ≈ $11.25 Million	Skr-49.80 Million ≈ $-5.36 Million	-0.476x	-325.45%
2020-12-31	Skr155.87 Million ≈ $16.77 Million	Skr-17.45 Million ≈ $-1.88 Million	-0.112x	+79.38%
2019-12-31	Skr18.34 Million ≈ $1.97 Million	Skr-9.96 Million ≈ $-1.07 Million	-0.543x	+48.59%
2018-12-31	Skr12.57 Million ≈ $1.35 Million	Skr-13.28 Million ≈ $-1.43 Million	-1.056x	-28.93%
2017-12-31	Skr1.45 Million ≈ $156.34K	Skr-1.19 Million ≈ $-128.07K	-0.819x	--

About Scandion Oncology A/S

ST:SCOL Sweden Biotechnology

Market Cap

$103.58K

Skr962.52K SEK

Market Cap Rank

#31491 Global

#746 in Sweden

Share Price

Skr0.00

Change (1 day)

+0.00%

52-Week Range

Skr0.00 - Skr0.00

All Time High

Skr22.90